Ascletis Announces Favorable and Differentiated Pharmacokinetic Profile of ASC30 Oral Once-Daily Tablet in Its U.S. Phase Ib Multiple Ascending Dose Study
- ASC30 oral once-daily tablet demonstrated approximately 2.3-fold to 3.3-fold greater drug exposure than orforglipron in a cross-trial comparison. - Higher drug exposure and favorable tolerability...
Could this differentiated PK profile lead to regulatory or partnership advantages compared to competitors, and what risks remain?
What are the anticipated timelines and success criteria for subsequent Phase II/III trials based on the Phase Ib data?
How will the reported 2.3‑3.3× higher exposure vs. orforglipron affect ASC's valuation and expected market share in the GLP‑1 agonist space?
about 21 hours ago